James & Esther King Biomedical Research Program Awards Peer-Reviewed Grant
SARASOTA, Fla., June 10 /PRNewswire/ -- The Roskamp Institute (Roskamp) today announced it was awarded the Florida Department of Health and James & Esther King Biomedical Research Program, Small Business Technology Transfer Grant for its advanced cancer research in using B-amyloid protein to stop the growth of lung cancer.
The grant in the amount of $100,000 was awarded to Roskamp's Investigator Daniel Paris, Ph.D. based on the scientific merit score Roskamp's proposal received through a competitive and qualified peer review process and the consideration of other factors by the Biomedical Research Advisory Council.
"This grant brings us one step closer to stopping the growth of lung cancer through our continued research with the use of B-amyloid protein," said Paris. "We are excited to have been awarded this grant, and we look forward to the advances we intend to make through our Institute's anti-cancer technology."
The peer-reviewed grant given to Roskamp for the "Treatment of Lung Adenocarcinoma and Metastasis by Anti-angiogenic Fragments of Abeta" project commences on July 1, 2008, and the life of the grant will be overseen by a grant manager of the James & Esther King Biomedical Research Program.
"The James & Esther King Program is known for its highly competitive grant award process, and we are honored to be a recipient," said Dr. Michael Mullan, director of Roskamp. "As a member of Florida's research community, we are committed to using this collaborative opportunity with small biomedical businesses and researchers alike to further our research advancements in hopes of curing this devastating disease."
The Roskamp Institute is a not-for-profit research Institute located in
Sarasota and Tampa, Florida, that is dedicated to understanding the causes
of, and finding cures for, neuropsychiatric and neurodegenerative disorders
and addictions with
|SOURCE Roskamp Institute|
Copyright©2008 PR Newswire.
All rights reserved